Gian Luca De Salvo

Head

Istituto Oncologico Veneto IOV-IRCCS

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gian Luca De Salvo is the Head at Istituto Oncologico Veneto IOV-IRCCS in Italy. His research focuses on oncology, particularly in the fields of sarcomas, prostate cancer imaging, and glioblastoma studies. Recent publications include analyses of rhabdomyosarcoma data, the effectiveness of imaging methods in cancer staging, and the prognostic factors in pediatric soft tissue sarcomas.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Gabriela Guillén Burrieza

Head of Section

Hospital Universitari Vall d'Hebron

SPAIN

View details

mario caccese

Istituto Oncologico Veneto

ITALY

View details

Gianni Bisogno

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gian Luca De Salvo

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data

Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial

A Prospective Randomized Multicenter Study on the Impact of [<sup>18</sup>F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer

Diagnostic Utility of a Modified Reticulin Algorithm in Pediatric Adrenocortical Neoplasms

REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma

Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram

Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients

Time to broaden the eligibility criteria in paediatric oncology trials? An analysis of patients with rhabdomyosarcoma non-eligible to the EpSSG RMS2005 trial

Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies

The impact of survivorship bias in glioblastoma research

The predictive role of intolerance of uncertainty and trait of worry in breast cancer patients: A prospective, observational, single-center clinical study

Administration of Samital<sup>®</sup> in children with oral mucositis: a feasibility study

Collaborators (3)

Gabriela Guillén Burrieza

mario caccese

Gianni Bisogno

Make your next move.